AtriCure (NASDAQ:ATRC) Issues FY 2026 Earnings Guidance

AtriCure (NASDAQ:ATRC) updated its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.240-0.320 for the period, compared to the consensus earnings per share estimate of 0.120. The company issued revenue guidance of $602.0 million-$610.0 million, compared to the consensus revenue estimate of $605.0 million.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ATRC. Freedom Capital upgraded shares of AtriCure to a “strong-buy” rating in a research note on Wednesday, April 1st. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research note on Tuesday. Raymond James Financial set a $52.00 price target on shares of AtriCure in a report on Tuesday. Canaccord Genuity Group raised their price target on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings downgraded shares of AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and a consensus price target of $49.12.

AtriCure Stock Performance

ATRC opened at $33.07 on Friday. The stock has a market cap of $1.67 billion, a PE ratio of -334.96 and a beta of 1.24. The company has a current ratio of 4.29, a quick ratio of 3.18 and a debt-to-equity ratio of 0.15. AtriCure has a 1 year low of $25.36 and a 1 year high of $43.18. The stock’s 50 day simple moving average is $29.91 and its 200-day simple moving average is $31.40.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a positive return on equity of 0.29% and a negative net margin of 0.83%.The firm had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. During the same period last year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Sell-side analysts forecast that AtriCure will post 0.13 EPS for the current year.

Insider Buying and Selling

In other AtriCure news, Director Karen Prange sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total transaction of $85,950.00. Following the completion of the transaction, the director owned 26,373 shares in the company, valued at $755,586.45. This trade represents a 10.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.00% of the stock is currently owned by corporate insiders.

AtriCure News Roundup

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure posted Q2 2026 EPS of $0.18, far above the $0.03 consensus estimate, while revenue of $153.6 million also beat expectations of $151.8 million. Article Title
• Positive Sentiment: The company raised FY 2026 guidance, with EPS outlook of $0.24 to $0.32 versus the prior consensus near $0.12, and revenue guidance of $602 million to $610 million, signaling management confidence in continued growth. Article Title
• Positive Sentiment: Management said Q2 delivered “healthy growth” and “a significant step up in profitability,” which may reinforce investor optimism about margin improvement. Article Title
• Neutral Sentiment: Several earnings call recap and transcript articles are circulating, but they largely repeat the same core takeaways from the release rather than adding new market-moving details. Article Title

Institutional Trading of AtriCure

Institutional investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC raised its stake in shares of AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 429 shares during the last quarter. Scotia Capital Inc. grew its position in AtriCure by 1.2% during the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock worth $1,328,000 after acquiring an additional 457 shares during the last quarter. Captrust Financial Advisors grew its position in AtriCure by 7.9% during the 4th quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock worth $314,000 after acquiring an additional 579 shares during the last quarter. Mackenzie Financial Corp increased its holdings in AtriCure by 5.3% during the 4th quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock valued at $545,000 after purchasing an additional 683 shares in the last quarter. Finally, California State Teachers Retirement System increased its holdings in AtriCure by 1.6% during the 2nd quarter. California State Teachers Retirement System now owns 45,001 shares of the medical device company’s stock valued at $1,475,000 after purchasing an additional 691 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.